Brief: Phio Pharmaceuticals Announces Regulatory Clearance Of Clinical Trial With Ph-762 And Agonox's Tumor Infiltrating Lymphocytes (Agx148) To Treat Solid Tumors
06/01/2023 21:04
Jan 6 (Reuters) - Phio Pharmaceuticals Corp PHIO.O :
* PHIO PHARMACEUTICALS ANNOUNCES REGULATORY CLEARANCE OF
CLINICAL
TRIAL WITH PH-762 AND AGONOX'S TUMOR INFILTRATING LYMPHOCYTES
(AGX148) TO TREAT SOLID TUMORS
Source text for Eikon: ID:nPnqQDmca
Further company coverage: PHIO.O
((Reuters.Briefs@thomsonreuters.com;;))
Recent news on Phio Pharmaceuticals
See all newsPhio Pharmaceuticals Q1 net loss widens on higher R&D costs
Brief: Phio Pharmaceuticals Corp - Enters At The Market Offering Agreement With H.C. Wainwright On April 8, 2026
Brief: Phio Pharmaceuticals Corp Announces Key Tumor Response Data From PH-762 Trial
Brief: Phio Pharmaceuticals Corp To Begin Toxicology Study For Ph-762 Before Human Trials - SEC Filing
Brief: Phio Pharmaceuticals Corp Files For Offering Of Up To 11.8 Million Common Shares By The Selling Stockholders - SEC Filing